MedTrace Logo

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

NCT05966584 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-08-29

Study results available
· View outcomes & findings →

Summary

The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib. Researchers think adding benralizumab to the standard-of-care hormone treatment and alpelisib may prevent the patient from getting a rash.

Conditions

Interventions

DRUG

Benralizumab

Benralizumab 30mg subcutaneously on day -1.

DRUG

fulvestrant or AIs) and PI3K inhibition (alpelisib)

SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)

Sponsors & Collaborators

Principal Investigators

  • Alina Markova, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2024-08-02
Completion
2024-08-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05966584 on ClinicalTrials.gov